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874Objectives: Cardiac arrest during cardiac surgery is most commonly induced by cold blood or cold crystalloid
cardioplegia. The results from clinical studies are divergent regarding which of the 2 solutions provides better
myocardial protection. This might be explained by several factors. Both heterogeneity in disease for the included
patients and the fact that most studies are retrospective in design and that patients with coronary artery disease
with different degrees of myocardial ischemia are included might explain these findings. To circumvent these
potentially confounding factors, we included in a prospective randomized study only patients undergoing aortic
valve replacement for aortic stenosis without other significant cardiac disease. Patients were randomized to
antegrade cold crystalloid or cold blood cardioplegia.
Methods: Eighty patients with aortic stenosis undergoing aortic valve replacement without significant coronary
artery stenosis or other significant concomitant heart valve disease were included in the study. They were random-
ized to either antegrade cold blood or cold crystalloid cardioplegic solution delivered through the coronary ostia
every 20 minutes throughout the period of aortic crossclamping. Maximum postoperative creatine kinase isoen-
zyme MB and troponin-T levels, well-established markers of myocardial damage, were compared between the 2
groups.
Results: Both maximum postoperative creatine kinase isoenzyme MB and troponin-T levels were significantly
higher by approximately 100% in the cohort of patients receiving crystalloid compared with blood cardioplegia.
Only in the group of patients receiving cold crystalloid cardioplegia was there a positive correlation between car-
diac enzyme levels and crossclamp time.
Conclusion: Antegrade cold blood cardioplegia provides better myocardial protection than cold crystalloid car-
dioplegia in patients undergoing aortic valve replacement. (J Thorac Cardiovasc Surg 2010;139:874-80)Over the past decades, the question of which cardioplegic
solution provides better myocardial protection during car-
diac surgery has been widely debated. Experimental studies
have suggested a favorable outcome1-4 for blood cardiople-
gia compared with crystalloid cardioplegia. Surprisingly,
however, clinical studies have not been conclusive regarding
which type of cardioplegia provides better protection.5,6
There are several possible reasons for this. First, in the ma-
jority of published studies, the groups of patients included
are heterogeneous with regard to a number of factors, such
as cause (ie, coronary artery disease, valvular disease, and
others), surgical procedure performed, and crossclampe Department of Cardiothoracic Surgery, Ulleva˚l University Hospital, Univer-
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The Journal of Thoracic and Cardiovascular Surgtime, possibly masking potential differences.5,6 A second
explanation might be that the crossclamp times in some stud-
ies are too short to demonstrate a difference that might
unmask itself with longer crossclamp times.7 A third expla-
nation might be that the chosen end points (eg, mortality and
hospital stay) are not discriminating well between the differ-
ences in protection. Moreover, various degrees of coronary
artery stenosis in the included patients might also mask
a potential difference because a prerequisite for comparing
2 cardioplegic solutions is that they reach the myocardium
to the same degree. Differences in the temperature of the
solutions, the composition of the different cardioplegic solu-
tions, and the means of application might also contribute to
difficulties in interpreting the results. To circumvent these
possible confounding factors, we decided to choose a homo-
geneous group of patients with potentially similar cross-
clamp times and without coronary artery disease. Thus
only patients with lone aortic stenosis were included in the
present study. The left ventricular hypertrophy in these
patients also makes their hearts vulnerable to ischemia,
which, theoretically, should make it easier to detect a poten-
tial difference in cardiac protection between the 2 solutions.
Thus the aim of the present study was to examine the effects
of 2 of the most frequently used cardioplegic solutions,ery c April 2010
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Dantegrade cold blood and antegrade cold crystalloid cardio-
plegia, on myocardial damage in patients with isolated aortic
stenosis undergoing aortic valve replacement. According to
statistical calculations before the start of the study, 80
patients were randomized to one of the 2 cardioplegic
solutions. Cardioplegia was performed under standardized
conditions, and creatine kinase isoenzyme MB (CK–MB)
and troponin-T levels, well-established markers of myocar-
dial damage, were used as indicators of myocardial damage.
MATERIALS AND METHODS
Study Population and Design
From November 2006 to February 2009, 80 consecutive patients under-
going elective aortic valve replacement at Ulleva˚l University Hospital, Oslo,
Norway, volunteered to participate and were included in the study. All
patients provided written consent. The local ethics committee approved
the study protocol. Eligible for operation were patients with a mean aortic
valve gradient of greater than 50 mm Hg or an aortic valve area of less
than 0.7 cm2 or symptomatic aortic valve stenosis. Before induction of
anesthesia, on the same day as the operation, patients were randomly allo-
cated to one of 2 groups, either receiving cold (4C–8C) crystalloid or
cold (4C–8C) blood cardioplegic solution. The randomization was
performed by opening sealed envelopes, and every cohort of 10 patients
was block randomized (5 to crystalloid and 5 to blood cardioplegia) to
ensure an even distribution of the 2 regimens with time.
Although cardioplegic solution is frequently administered in a retrograde
manner through the coronary sinus, this procedure might provide an inade-
quate protection of the right ventricle unless combined with antegrade admin-
istration of cardioplegic solution through the right coronary ostium. For the
sake of simplicity, in the present study cardioplegic solution was delivered
in an antegrade fashion only through the coronary ostia strictly every 20
minutes with a pressure of 300 mm Hg or less with a Sto¨ckert roller pump
(Sto¨ckert Instrumente GmbH, Munich, Germany) throughout the period of
aortic crossclamping. Initially, 400 mL of cardioplegic solution was admin-
istrated immediately after asystole. Every 20 minutes, 300 to 400 mL was ad-
ministrated into the left coronary ostium and 200 to 300 mL into the right
coronary ostium, taking the size of the heart into consideration.
Patients with significant coronary artery stenoses (50%) or other sig-
nificant concomitant heart valve disease were excluded from the study.
Ten patients were also excluded from the study after randomization (5 pa-
tients in each group) for the following reasons. In the group receiving blood
cardioplegia, 4 patients were excluded because they needed additional car-
dioplegia (because of emergence of spontaneous heart rhythm after 10–12
minutes) before that scheduled by the protocol. One patient was excluded
because the heart did not stop and the surgeon decided to open the aorta
and administer cardioplegic solution directly into the coronary ostia. In
the group receiving crystalloid cardioplegia, 2 patients were excluded
because they needed additional cardioplegia (because of emergence of
spontaneous heart rhythm after 10–13 minutes) before that scheduled by
the protocol. Two patients were excluded because the heart did not stop ini-
tially and the surgeon decided to open the aorta and administer cardioplegic
solution directly into the coronary ostia. One patient was excluded because
the second shot of cardioplegic solution was administered 30 minutes after
the first (and not 20 minutes, as decided by the protocol).The Journal of Thoracic and CaAnesthesia and Operative Technique
Patients underwent operations as previously described.8 Anesthesia was in-
duced with diazepam (0.1–0.2 mg/kg), fentanyl (3–5 mg/kg), thiopental (0.5–
2.0 mg/kg), and cisatracurium (0.15 mg/kg) and maintained with sevoflurane
(1% to 2% inspired). Midazolam (0.02–0.04 mg/kg) and fentanyl (1–2mg/kg)
were administered in addition to sevoflurane during cardiopulmonary bypass.
Anticoagulation was accomplished with systemic heparinization (4 mg/kg
body weight) and supplemented as required to maintain an activated clotting
time of greater than 480 seconds. All operations were performed by using
the standard technique of cardiopulmonary bypass with extracorporeal circu-
lation with a Sto¨ckert roller pump, ascending aortic cannulation, single venous
cannulation, and moderate systemic hypothermia (32C).Myocardial Protection
One of the following 2 cardioplegic solutions was used for myocardial
protection.
Crystalloid cardioplegia. We used a modified St Thomas II cardi-
oplegic solution. One liter of crystalloid cardioplegic solution contains the
following components: potassium, 19.6 mmol/L; magnesium, 16.7 mmol/
L; calcium, 2.0 mmol/L; sodium, 128.0 mmol/L; procaine hydrochloride,
1.0 mmol/L; acetate, 29.4 mmol/L, and chloride 157.8 mmol/L (pH 6.3;
temperature, 4C – 8C).
Blood cardioplegia. One liter of blood cardioplegic solution con-
tains the following components: potassium, 21.5 mmol/L; magnesium,
18.2 mmol/L; calcium, 2.2 mmol/L; sodium, 145.1 mmol/L; procaine hy-
drochloride, 1.1 mmol/L; acetate, 6.5 mmol/L; chloride, 154.9 mmol/L;
and hydrogen carbonate, 28.9 mmol/L (pH 7.4; temperature, 4C – 8C).Use of Inotropic Support and Postarrest Recovery
Time
We measured the time from release of the aortic crossclamp until wean-
ing from extracorporeal circulation and registered the use of inotropic infu-
sions for longer than 20 minutes in the first 24 postoperative hours.
Registration of Postoperative Atrial Fibrillation
A 12–lead electrocardiogram (ECG) was recorded daily on the first 3
postoperative days and compared with the ECG before surgical interven-
tion. All patients were also monitored with telemetry continuously for the
3 first postoperative days. Patients who had 1 or more episodes of atrial fi-
brillation postoperatively without a history of atrial fibrillation preopera-
tively were registered.
Measurements of Cardiac Marker Proteins
We collected venous blood samples before the operation and 7, 20, 44,
and 68 hours postoperatively. The time points were chosen because of the
profile of the enzyme release in plasma after myocardial ischemia.9
CK-MB and troponin-T levels were immediately analyzed in the Depart-
ment of Clinical Chemistry at Ulleva˚l University Hospital, as previously
described.10 The serum cardiac troponin-T level was determined by using
an electrochemiluminescence immunoassay on the Roche Elecsys 2010
immunoassay analyzer (Roche Diagnostics, Mannheim, Germany). The
upper normal reference limit (99th percentile) is less than 0.10 ng/mL.
The serum CK-MB level was determined by using an electrochemilumines-
cence immunoassay on the Roche Elecsys 2010 immunoassay analyzer. The
upper normal reference limit (99th percentile) is less than 5 ng/mL.
Criteria for Perioperative Myocardial Infarction
According to guidelines set by our department, 2 of the 3 following cri-
teria had to be fulfilled: (1) CK-MB level of 100 mg/L or greater, troponin-T
level of 3.0 mg/L or greater, or both; (2) development of a new Q-wave on an
ECG of more than 0.03 seconds postoperatively; and (3) development ofrdiovascular Surgery c Volume 139, Number 4 875
TABLE 1. Patient characteristics
Characteristics
Blood
cardioplegia*
Crystalloid
cardioplegia* P value
Age (y) 68.2  2.0 71.3  1.5 .21
Female sex (no.) 18 14 .47
Extracorporeal
circulation (min)
103.6  3.6 105.8  3.1 .64
Crossclamp time (min) 74.4  3.6 75.6  3.1 .80
Postarrest recovery
(min)
23.1  1.1 24.1  1.1 .53
Preoperative
creatinine (mmol/L)
83.1  3.8 79.9  3.3 .53
Postoperative
creatinine (mmol/L)
82.5  5.3 80.3  4.4 .76
Postoperative
inotropic
infusion (no.)
1 1 1.00
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Da new hypokinetic or akinetic area in the left or right ventricle, as determined
by means of echocardiographic analysis.
Statistical Analysis
Data are presented as means  standard error of the mean. They were
analyzed with SigmaStat, version 3.1 (Jandel Scientific GmbH, Erkrath,
Germany). A 50% difference between groups regarding markers of myocar-
dial damage was considered significant to calculate sample size. Based on
the results from a previous study,8 our study with 80 patients would result
in a power of 0.99 with a P value of .05. Differences between the 2 groups
were analyzed by using the Student’s t test or the Mann–Whitney rank sum
test for data normally or not normally distributed, respectively. Differences
within groups over time were analyzed by using analysis of variance for re-
peated measures and corrected for multiple comparisons. Data not normally
distributed were transformed by means of natural logarithm to fit a normal
distribution when examining the relation between 2 continuous variables by
means of linear regression. Comparisons of groups with dichotomous data
were analyzed by using the Fisher’s exact test or the c2 test. P< .05 was
considered as statistically significant.Postoperative AF (no.) 13 15 .81
30-d Mortality (no.) 0 0
IVSd (cm) 1.3  0.03 1.3  0.05 .52
Myocardial infarction
(no.)
0 0
Preoperative EF 51% 51% .24
Preoperative use of
b-blockers
29% 34% .80
Postoperative use of
b-blockers
82% 82% 1.00RESULTS
Patient characteristics are shown in Table 1. We did not
find any significant differences regarding any of the vari-
ables presented in the table. There was no 30-day mortality
in either of the groups. There were no differences in the
frequency of atrial fibrillation, time from weaning from
extracorporeal circulation, inotropic support, or myocardial
infarction in the 2 groups.
Defibrillation after
crossclamp removal
(no.)
2 1 1.00
Amounts of
cardioplegia (mL)
2195.7  106.5 2018.6  64.3 .26
Lowest core
temperature under
Extracorporeal
Circulation (C)
32.7  0.1 32.7  0.1 1.00
AF, Atrial fibrillation; IVSd, interventricular septal thickness at end-diastole; EF, ejec-
tion fraction. *Values are presented as means  standard error of the mean, where
shown.CK-MB
There were approximately 100% higher maximum
CK-MB levels in the group of patients receiving cold crystal-
loid cardioplegia (Figure 1) compared with those receiving
cold blood cardioplegia (56.1  13.9 and 29.3  1.5 mg/L,
respectively). The highest levels were found 7 hours after
the operation (Figure 2). Three patients in the study population
had postoperative CK-MB levels of greater than 100 mg/L,
which is suspicious of a perioperative myocardial infarction.
All of these patients received cold crystalloid cardioplegia.
However, none of these patients showed other signs of myo-
cardial infarction on echocardiographic or ECG analysis and
were thus not classified as having myocardial infarction ac-
cording to our criteria. In Figure 3 the maximum CK-MB level
is plotted against crossclamp time in the 2 groups. This figure
shows that in patients receiving cold blood cardioplegia, there
was no correlation between maximum CK-MB level and
crossclamp time at up to 2 hours of crossclamping. In the
group receiving cold crystalloid cardioplegia, however, there
was a significant correlation between maximum CK-MB level
and crossclamp time (R¼ 0.42, P¼ .01). There was no corre-
lation between CK-MB levels and the amount of cardioplegic
solution administered in either group.Troponin-T
As with CK-MB, the maximum troponin-T level was
approximately 100% higher in the group of patients receiv-876 The Journal of Thoracic and Cardiovascular Surging cold crystalloid cardioplegia compared with that seen in
the patients receiving cold blood cardioplegia (1.21  0.37
and 0.58  0.05 mg/L, respectively). Troponin-T was not
detectable before the operation and showed the highest
levels in the first postoperative set of blood samples and de-
creased levels in the following 3 sets (Figure 2). There was
a significant correlation between maximum troponin-T level
and crossclamp time (Figure 3) only in the group of patients
receiving cold crystalloid cardioplegia (R ¼ 0.37, P ¼ .03).
There was no correlation between troponin-T levels and the
amount of cardioplegic solution administered in either
group.DISCUSSION
The present prospective randomized study demonstrates
clearly that markers of myocardial damage wereery c April 2010
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FIGURE 2. Panel A shows creatine kinase isoenzyme MB (CK-MB) levels
preoperatively (Preop.) and 7, 20, 44, and 68hours (h) postoperatively (PO).
Panel B shows troponin-T levels preoperatively and 7, 20, 44, and 68hours
postoperatively. *P< .05 compared with preoperative values.
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FIGURE 1. Panel A shows maximum (Max) postoperative creatine kinase
isoenzyme MB (CK-MB) levels with blood and crystalloid cardioplegia.
Panel B shows maximum postoperative troponin-T levels with blood and
crystalloid cardioplegia. *P< .05 compared with blood cardioplegia.
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Dsignificantly lower in patients undergoing operations for aor-
tic stenosis who were randomized to cold blood cardioplegia
compared with those receiving cold crystalloid cardioplegia.
Moreover, we found a positive correlation between cardiac
enzyme levels and crossclamp time only in the group of pa-
tients receiving cold crystalloid cardioplegia. No difference
in the frequency of atrial fibrillation, inotropic support, myo-
cardial infarction, or mortality was detected between groups.
Experimental studies1-4 have reported a favorable effect
of blood cardioplegia over crystalloid cardioplegia in induc-
ing cardiac arrest. The results from clinical studies have been
less convincing.5,6 The reasons for this might be many.
Several studies are retrospective in design with historical
data,11-14 and many studies also include patients with
a wide range of cardiac pathologies, surgical procedures,
and crossclamp times.5,6 This might mask a potential differ-
ence in end points between blood and crystalloid cardiople-The Journal of Thoracic and Cagia. Moreover, almost all published studies include patients
with coronary artery disease of various degrees,5,6 and cor-
onary artery stenoses might in turn result in an uneven dis-
tribution of cardioplegia within the myocardium and thus
increase the variation of protection and measured end points
and mask a potential effect. In one well-performed, large,
prospective randomized study by Øvrum and coworkers,7
no difference in clinical outcome was detected between
blood and crystalloid cardioplegia in patients undergoing
coronary artery bypass grafting surgery. In that study, how-
ever, mean crossclamp time was only 34 minutes, and this
might be too short to demonstrate a potential difference.
Markers of myocardial damage were also not given in that
study. Although a few clinical studies have reported a favor-
able effect of blood cardioplegia,15-18 others have not been
able to demonstrate any difference,7,19-22 and in some
a worse outcome for patients receiving cold blood cardiople-
gia has been reported.23
In our opinion the optimal group of patients to demon-
strate a potential benefit for blood over crystalloid cardiople-
gia would be patients undergoing cardiac surgery withrdiovascular Surgery c Volume 139, Number 4 877
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FIGURE 3. Panels A and B show no correlation between cardiac enzyme levels and crossclamp times in the group of patients receiving cold blood cardi-
oplegia. Panels C and D show a positive correlation between cardiac enzyme levels and crossclamp times in the group of patients receiving cold crystalloid
cardioplegia. Dashed lines show 95% confidence and prediction intervals. Max, Maximal; CK-MB, creatine kinase isoenzyme MB.
Acquired Cardiovascular Disease Braathen and Tønnessen
A
C
Drelatively long crossclamp times, with no compromised cor-
onary flow to ensure the full effect of the cardioplegic solu-
tion, and with a disease susceptible to ischemia. Therefore
patients undergoing aortic valve replacement with no coro-
nary artery disease would be ideal to test the hypothesis878 The Journal of Thoracic and Cardiovascular Surgthat cold blood cardioplegia provides better protection of
the myocardium than cold crystalloid cardioplegia. This is
a fairly homogenous group of patients with approximate
expected crossclamp times of about 75 minutes in our de-
partment, and the myocardial hypertrophy makes the heartery c April 2010
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Dsusceptible to ischemia, which would make it easier to detect
a possible difference between groups. Surprisingly, we have
only been able to find 1 prospective randomized study
comparing cold blood and cold crystalloid cardioplegia in
patients undergoing aortic stenosis without coronary artery
disease. In that study by Bouchart and colleagues,23 cold
blood cardioplegia resulted in higher levels of CK-MB com-
pared with cold crystalloid cardioplegia, which is contrary to
expectations. The study did not provide any answer for this
unexpected finding. However, no power analysis was pre-
sented in the study, and they compared statistically 3 groups
of only 20 patients, which makes a type I statistical error (ie,
a false-positive result) possible. In another study by Jin and
associates,24 antegrade and retrograde cold blood cardiople-
gia resulted in better preservation of myocardial physiologic
response and less inotropic support. However, this study in-
cluded a mixed group of patients in which more than a third
of the patients received concomitant coronary artery bypass
grafting. Furthermore, CK-MB levels, troponin-T levels, or
other markers of myocardial damage were not measured. We
think it is important to measure markers of myocardial dam-
age because these most likely would discriminate better be-
tween beneficial effects than clinical outcome. The ability to
detect differences in hard clinical end points, such as mortal-
ity, often requires a much larger number of patients in each
group than presented in most published studies. It should be
noted that none of our patients died within 30 days of surgi-
cal intervention, and according to our criteria, none had
a perioperative myocardial infarction.
In the present study patients receiving cold crystalloid car-
dioplegia had approximately double the circulating levels of
CK-MB and troponin-T than patients receiving cold blood
cardioplegia, indicating greater myocardial damage. An-
other interesting finding was the significant positive correla-
tion between crossclamp time up to 2 hours and cardiac
enzyme levels in patients receiving cold crystalloid cardio-
plegia only. The R2 values were 0.14 and 0.18 for tropo-
nin-T and CK-MB, respectively, suggesting that 14% and
18% of the increase in enzyme levels is explained by the
crossclamp time. Because there was no significant correla-
tion between crossclamp time and markers of myocardial
damage in the group receiving cold blood cardioplegia in
the same time span, this suggests, together with the lower
release of troponin-T and CK-MB, that cold blood cardio-
plegia provides better cardioprotection than crystalloid car-
dioplegia in patients undergoing aortic valve replacement.
Of course, it could be argued that clinical differences and
not enzyme levels of myocardial damage are the most impor-
tant end points when comparing 2 regimens of cardioplegia.
Nevertheless, we think that the clearly lower enzyme levels
in the group receiving cold blood cardioplegia advocate for
this cardioplegic regimen in high-risk patients or patients un-
dergoing complex surgical procedures. It should also be
noted that Nesher and colleagues25 have shown a correlationThe Journal of Thoracic and Cabetween troponin-T levels after cardiac surgery and a com-
posite end point of death, electrocardiographically defined
infarction, and low output syndrome (major adverse cardiac
events). Furthermore, Lehrke and coworkers26 reported
a significant correlation between troponin-T levels postoper-
atively and long-term survival after cardiac surgery.
The exact mechanism for the lower enzyme release in the
blood cardioplegia group was not examined in the present
study. The differences in concentrations of electrolytes
between the 2 cardioplegic solutions might contribute to
this finding. Moreover, delivery of oxygenated blood to
the cardiomyocytes, a more effective buffer system, and
a better and more uniform capillary flow have also been sug-
gested as mechanisms behind a better protection with blood
cardioplegia.2
In the present study we could not demonstrate any signif-
icant differences in atrial fibrillation, use of inotropic sup-
port, and postarrest recovery time in the 2 cardioplegia
groups. These findings are in accordance with those of pre-
viously published studies.7,21 However, it should be noted
that our study was not designed to answer these questions
and might thus be underpowered.Study Limitations
This study has some limitations. First, the surgeons were
not blind to which type of cardioplegia was being used.
Moreover, the power calculations were made to ensure
a high enough power regarding comparisons of postopera-
tive cardiac enzyme release. With regard to clinical end
points, however, there might be too few patients to rule
out a type II statistical error.CONCLUSION
For the first time, we have, in patients undergoing opera-
tions for isolated aortic stenosis, demonstrated in a prospec-
tive randomized study that markers of myocardial damage
are significantly lower in patients randomized to cold blood
cardioplegia compared with those receiving cold crystalloid
cardioplegia. We also found a positive correlation between
cardiac enzyme levels and crossclamp time only in the group
of patients receiving cold crystalloid cardioplegia.
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